Progressive disease in glioblastoma: Benefits and limitations of semi-automated volumetry.
PURPOSE:Unambiguous evaluation of glioblastoma (GB) progression is crucial, both for clinical trials as well as day by day routine management of GB patients. 3D-volumetry in the follow-up of GB provides quantitative data on tumor extent and growth, and therefore has the potential to facilitate objec...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5330491?pdf=render |
| _version_ | 1818360577519517696 |
|---|---|
| author | Thomas Huber Georgina Alber Stefanie Bette Johannes Kaesmacher Tobias Boeckh-Behrens Jens Gempt Florian Ringel Hanno M Specht Bernhard Meyer Claus Zimmer Benedikt Wiestler Jan S Kirschke |
| author_facet | Thomas Huber Georgina Alber Stefanie Bette Johannes Kaesmacher Tobias Boeckh-Behrens Jens Gempt Florian Ringel Hanno M Specht Bernhard Meyer Claus Zimmer Benedikt Wiestler Jan S Kirschke |
| author_sort | Thomas Huber |
| collection | DOAJ |
| description | PURPOSE:Unambiguous evaluation of glioblastoma (GB) progression is crucial, both for clinical trials as well as day by day routine management of GB patients. 3D-volumetry in the follow-up of GB provides quantitative data on tumor extent and growth, and therefore has the potential to facilitate objective disease assessment. The present study investigated the utility of absolute changes in volume (delta) or regional, segmentation-based subtractions for detecting disease progression in longitudinal MRI follow-ups. METHODS:165 high resolution 3-Tesla MRIs of 30 GB patients (23m, mean age 60.2y) were retrospectively included in this single center study. Contrast enhancement (CV) and tumor-related signal alterations in FLAIR images (FV) were semi-automatically segmented. Delta volume (dCV, dFV) and regional subtractions (sCV, sFV) were calculated. Disease progression was classified for every follow-up according to histopathologic results, decisions of the local multidisciplinary CNS tumor board and a consensus rating of the neuro-radiologic report. RESULTS:A generalized logistic mixed model for disease progression (yes / no) with dCV, dFV, sCV and sFV as input variables revealed that only dCV was significantly associated with prediction of disease progression (P = .005). Delta volume had a better accuracy than regional, segmentation-based subtractions (79% versus 72%) and a higher area under the curve by trend in ROC curves (.83 versus .75). CONCLUSION:Absolute volume changes of the contrast enhancing tumor part were the most accurate volumetric determinant to detect progressive disease in assessment of GB and outweighed FLAIR changes as well as regional, segmentation-based image subtractions. This parameter might be useful in upcoming objective response criteria for glioblastoma. |
| first_indexed | 2024-12-13T21:03:00Z |
| format | Article |
| id | doaj.art-983ed96931a14d638b4be72e09b70ede |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-13T21:03:00Z |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-983ed96931a14d638b4be72e09b70ede2022-12-21T23:31:34ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01122e017311210.1371/journal.pone.0173112Progressive disease in glioblastoma: Benefits and limitations of semi-automated volumetry.Thomas HuberGeorgina AlberStefanie BetteJohannes KaesmacherTobias Boeckh-BehrensJens GemptFlorian RingelHanno M SpechtBernhard MeyerClaus ZimmerBenedikt WiestlerJan S KirschkePURPOSE:Unambiguous evaluation of glioblastoma (GB) progression is crucial, both for clinical trials as well as day by day routine management of GB patients. 3D-volumetry in the follow-up of GB provides quantitative data on tumor extent and growth, and therefore has the potential to facilitate objective disease assessment. The present study investigated the utility of absolute changes in volume (delta) or regional, segmentation-based subtractions for detecting disease progression in longitudinal MRI follow-ups. METHODS:165 high resolution 3-Tesla MRIs of 30 GB patients (23m, mean age 60.2y) were retrospectively included in this single center study. Contrast enhancement (CV) and tumor-related signal alterations in FLAIR images (FV) were semi-automatically segmented. Delta volume (dCV, dFV) and regional subtractions (sCV, sFV) were calculated. Disease progression was classified for every follow-up according to histopathologic results, decisions of the local multidisciplinary CNS tumor board and a consensus rating of the neuro-radiologic report. RESULTS:A generalized logistic mixed model for disease progression (yes / no) with dCV, dFV, sCV and sFV as input variables revealed that only dCV was significantly associated with prediction of disease progression (P = .005). Delta volume had a better accuracy than regional, segmentation-based subtractions (79% versus 72%) and a higher area under the curve by trend in ROC curves (.83 versus .75). CONCLUSION:Absolute volume changes of the contrast enhancing tumor part were the most accurate volumetric determinant to detect progressive disease in assessment of GB and outweighed FLAIR changes as well as regional, segmentation-based image subtractions. This parameter might be useful in upcoming objective response criteria for glioblastoma.http://europepmc.org/articles/PMC5330491?pdf=render |
| spellingShingle | Thomas Huber Georgina Alber Stefanie Bette Johannes Kaesmacher Tobias Boeckh-Behrens Jens Gempt Florian Ringel Hanno M Specht Bernhard Meyer Claus Zimmer Benedikt Wiestler Jan S Kirschke Progressive disease in glioblastoma: Benefits and limitations of semi-automated volumetry. PLoS ONE |
| title | Progressive disease in glioblastoma: Benefits and limitations of semi-automated volumetry. |
| title_full | Progressive disease in glioblastoma: Benefits and limitations of semi-automated volumetry. |
| title_fullStr | Progressive disease in glioblastoma: Benefits and limitations of semi-automated volumetry. |
| title_full_unstemmed | Progressive disease in glioblastoma: Benefits and limitations of semi-automated volumetry. |
| title_short | Progressive disease in glioblastoma: Benefits and limitations of semi-automated volumetry. |
| title_sort | progressive disease in glioblastoma benefits and limitations of semi automated volumetry |
| url | http://europepmc.org/articles/PMC5330491?pdf=render |
| work_keys_str_mv | AT thomashuber progressivediseaseinglioblastomabenefitsandlimitationsofsemiautomatedvolumetry AT georginaalber progressivediseaseinglioblastomabenefitsandlimitationsofsemiautomatedvolumetry AT stefaniebette progressivediseaseinglioblastomabenefitsandlimitationsofsemiautomatedvolumetry AT johanneskaesmacher progressivediseaseinglioblastomabenefitsandlimitationsofsemiautomatedvolumetry AT tobiasboeckhbehrens progressivediseaseinglioblastomabenefitsandlimitationsofsemiautomatedvolumetry AT jensgempt progressivediseaseinglioblastomabenefitsandlimitationsofsemiautomatedvolumetry AT florianringel progressivediseaseinglioblastomabenefitsandlimitationsofsemiautomatedvolumetry AT hannomspecht progressivediseaseinglioblastomabenefitsandlimitationsofsemiautomatedvolumetry AT bernhardmeyer progressivediseaseinglioblastomabenefitsandlimitationsofsemiautomatedvolumetry AT clauszimmer progressivediseaseinglioblastomabenefitsandlimitationsofsemiautomatedvolumetry AT benediktwiestler progressivediseaseinglioblastomabenefitsandlimitationsofsemiautomatedvolumetry AT janskirschke progressivediseaseinglioblastomabenefitsandlimitationsofsemiautomatedvolumetry |